Cresco Labs Inc.
CNSX:CL Stock Report
Cresco Labs Past Earnings Performance Cresco Labs's earnings have been declining at an average annual rate of -16.7%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually. Revenues have been growing at an average rate of 21.8% per year.
Key information
-16.7%
Earnings growth rate
Pharmaceuticals Industry Growth 23.1% Revenue growth rate 21.8% Return on equity -15.3% Net Margin -9.2% Last Earnings Update 30 Sep 2024
Recent past performance updates
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 10
Cresco Labs Inc. to Report Q3, 2024 Results on Nov 08, 2024 Oct 17
Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.12 loss in 2Q 2023) Aug 09
Cresco Labs Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 23
First quarter 2024 earnings released: US$0.015 loss per share (vs US$0.085 loss in 1Q 2023) May 19
Cresco Labs Inc. to Report Q1, 2024 Results on May 15, 2024 May 01
Show all updates
No longer forecast to breakeven Nov 11
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 10
Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely Oct 24
Cresco Labs Inc. to Report Q3, 2024 Results on Nov 08, 2024 Oct 17
Cresco Labs Inc. Announces Resignation of Tarik Brooks as Board of Directors Sep 29 Cresco Labs Inc. Announces CFO Changes Sep 12
New minor risk - Profitability Sep 11
No longer forecast to breakeven Sep 11
Co-Founder & Independent Director recently sold CA$110k worth of stock Sep 01
Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates Aug 11
Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.12 loss in 2Q 2023) Aug 09
Cresco Labs Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 23
Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%? Jul 17
Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden Jun 19
Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio Jun 19
Co-Founder & Independent Director recently sold CA$236k worth of stock Jun 18
New minor risk - Shareholder dilution Jun 11
Co-Founder & Independent Director recently sold CA$124k worth of stock Jun 09
Co-Founder & Independent Director recently sold CA$124k worth of stock Jun 04
Co-Founder & Independent Director recently sold CA$364k worth of stock May 28
First quarter 2024 earnings released: US$0.015 loss per share (vs US$0.085 loss in 1Q 2023) May 19
Cresco Labs Inc. (CNSX:CL) acquired Two medical dispensaries in Pennsylvania of Keystone Integrated Care, LLC for $9.8 million. May 17
Consensus EPS estimates upgraded to US$0.055 loss May 16
Cresco Labs Inc. to Report Q1, 2024 Results on May 15, 2024 May 01
Cresco Labs Inc., Annual General Meeting, Jun 10, 2024 Apr 11
Forecast to breakeven in 2026 Apr 09
Consensus EPS estimates upgraded to US$0.059 loss Mar 24
Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41 Mar 16
New minor risk - Profitability Mar 15
Full year 2023 earnings released: US$0.53 loss per share (vs US$0.71 loss in FY 2022) Mar 13
Forecast to breakeven in 2025 Mar 13
New minor risk - Shareholder dilution Mar 11
Chief Financial Officer exercised options to buy CA$150k worth of stock. Mar 07
Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32% Mar 03
Cresco Labs Inc. to Report Q4, 2023 Results on Mar 13, 2024 Feb 28
Cresco Labs Inc. Promotes Greg Butler to the Position of President Feb 01
Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt Jan 26
New minor risk - Shareholder dilution Jan 22
Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL) Jan 04
New minor risk - Shareholder dilution Dec 11
Consensus EPS estimates fall by 91%, revenue upgraded Nov 24
Third quarter 2023 earnings released: US$0.34 loss per share (vs US$0.033 loss in 3Q 2022) Nov 17
Cresco Labs Inc. to Report Q3, 2023 Results on Nov 15, 2023 Nov 02
New major risk - Share price stability Nov 01
Cresco Labs Inc. completed the acquisition of Sole Licensed Arizona Operation of Cresco Labs Inc. Oct 20
No longer forecast to breakeven Sep 25
Is Cresco Labs (CSE:CL) Using Too Much Debt? Sep 22
New minor risk - Shareholder dilution Sep 11
Consensus EPS estimates fall by 42% Aug 24
Chief Financial Officer recently bought CA$149k worth of stock Aug 20
Price target decreased by 8.4% to CA$4.80 Aug 17
Cresco Labs Inc. Provides Revenue Guidance for the Second Half of 2023 Aug 17
Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.046 loss in 2Q 2022) Aug 17
Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 33% Aug 11
Cresco Labs Inc. to Report Q2, 2023 Results on Aug 16, 2023 Aug 03
Insufficient new directors Aug 01
Consensus EPS estimates fall by 15% May 31
Price target decreased by 36% to CA$3.82 May 29
First quarter 2023 earnings released: US$0.092 loss per share (vs US$0.094 loss in 1Q 2022) May 26
Cresco Labs Inc. to Report Q1, 2023 Results on May 24, 2023 May 13
Consensus EPS estimates fall by 40% Apr 19
Insider recently sold CA$157k worth of stock Mar 29
Consensus EPS estimates fall by 109% Mar 28
Full year 2022 earnings released: US$0.71 loss per share (vs US$1.22 loss in FY 2021) Mar 17
Cresco Labs (CSE:CL) Has A Somewhat Strained Balance Sheet Jan 25
Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 24%? Dec 13
Now 22% undervalued after recent price drop Dec 08
Co-Founder & Independent Director recently sold CA$1.7m worth of stock Dec 04
Forecast breakeven date moved forward to 2023 Dec 03
Forecast breakeven date pushed back to 2024 Nov 22
Now 20% undervalued after recent price drop Nov 18
Third quarter 2022 earnings released: US$0.011 loss per share (vs US$1.00 loss in 3Q 2021) Nov 16
Combs Enterprises signed a definitive agreements to acquire Certain New York, Illinois, and Massachusetts assets of Cresco Labs Inc. and Columbia Care Inc. for approximately $190 million. Nov 05
Price target decreased to CA$10.10 Nov 03
Consensus forecasts updated Oct 28
Cresco Labs Inc. to Report Q3, 2022 Results on Nov 15, 2022 Oct 28
Cresco Labs Inc. Announces Resignation of Sidney Dillard from the Board of Director Oct 25
Aventine Property Group, Inc. acquired Cresco Labs Facility in Brookville, PA for $45 million Sep 08
Consensus EPS estimates fall by 178% Aug 25
We Think Cresco Labs (CSE:CL) Is Taking Some Risk With Its Debt Aug 22
Second quarter 2022 earnings: EPS exceeds analyst expectations Aug 19
High number of new directors Aug 19
Cresco Labs Inc. to Report Q2, 2022 Results on Aug 17, 2022 Aug 02
Forecast breakeven date moved forward to 2022 Jul 20
Co-Founder exercised options to buy CA$627k worth of stock. Jun 02
Chief Financial Officer recently bought CA$104k worth of stock May 27
Estimating The Intrinsic Value Of Cresco Labs Inc. (CSE:CL) May 23
Price target decreased to CA$15.38 May 21
Forecast breakeven date pushed back to 2023 May 19
Cresco Labs Inc. to Report Q1, 2022 Results on May 18, 2022 May 07
High number of new directors Apr 27
Cresco Labs Inc., Annual General Meeting, Jun 30, 2022 Apr 24
Price target decreased to CA$17.13 Apr 19
Revenue & Expenses Breakdown
How Cresco Labs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History CNSX:CL Revenue, expenses and earnings (USD Millions) Date Revenue Earnings G+A Expenses R&D Expenses 30 Sep 24 733 -67 247 0 30 Jun 24 735 -172 227 0 31 Mar 24 747 -155 241 0 31 Dec 23 756 -176 260 0 30 Sep 23 767 -339 283 0 30 Jun 23 786 -234 295 0 31 Mar 23 806 -211 307 0 31 Dec 22 825 -212 310 0 30 Sep 22 842 -65 295 0 30 Jun 22 848 -326 295 0 31 Mar 22 841 -318 292 0 31 Dec 21 806 -320 276 0 30 Sep 21 750 -360 276 0 30 Jun 21 687 -73 246 0 31 Mar 21 573 -105 215 0 31 Dec 20 463 -102 199 0 30 Sep 20 345 -76 163 0 30 Jun 20 231 -98 145 0 31 Mar 20 168 -64 119 0 31 Dec 19 124 -43 92 0 30 Sep 19 101 -20 77 0 30 Jun 19 78 -14 63 0 31 Mar 19 57 -12 46 0 31 Dec 18 41 -2 31 0 30 Sep 18 28 0 19 0 30 Jun 18 19 1 9 0 31 Mar 18 13 1 7 0 31 Dec 17 10 -3 5 0 31 Dec 16 3 -8 4 0
Quality Earnings: CL is currently unprofitable.
Growing Profit Margin: CL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CL is unprofitable, and losses have increased over the past 5 years at a rate of 16.7% per year.
Accelerating Growth: Unable to compare CL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).
Return on Equity
High ROE: CL has a negative Return on Equity (-15.34%), as it is currently unprofitable.
Return on Capital Employed
Discover strong past performing companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
